AmMax Bio Announces First Patient Dosed in Phase 2a Study Evaluating AMB-066 in Patients with Colorectal Cancer Minimal Residual Disease
AMB-066 is a potential first-in-class treatment for CRC MRD ~20,000 patients diagnosed annually in U.S.; no currently approved therapies ...